Home > News > Veristat congratulates awakn uk state funding to identify optimal pathway to market in uk us

1 min read

Veristat congratulates Awakn - UK State Funding to Identify Optimal Pathway to Market In UK & US

Clinical Trials Success Stories Regulatory Submissions
Veristat congratulates Awakn for being awarded UK State Funding to Identify Optimal Pathway to Market In UK & US For Its Lead Clinical Development Program – Ketamine-Assisted Therapy For Alcohol Use Disorder

Awakn Life Sciences Corp. (NEO: AWKN, OTCQB: AWKNF, FSE: 954), a revenue-generating biotechnology company researching, developing and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), is pleased to announce it has secured funding from Innovate UK to identify the quickest and most cost-effective route to market in both the UK and the US for Awakn’s lead program - proprietary ketamine-assisted therapy for treating AUD. Innovate UK is the UK’s national innovation agency which provided the funding in an initiative delivered jointly by CPI and ABHI.

Awakn’s activities will be delivered in collaboration with Veristat, a global Clinical Research Organization (CRO) that specialises in accelerating client therapies through the clinical development process into regulatory approval and commercialization. Veristat supported marketing applications for 12% of all US Food and Drug Administration (FDA) Novel Drug Approvals in 2021.  

Read full Awakn Press Release

 

1 min read

Meet Veristat at BIO-Europe Spring: March 23-25, 2026 - Lisbon, Portugal

Mar 23, 2026  Veristat Events

🔬 Connecting with the Global Biopharma Community

Veristat is pleased to attend BIO-Europe Spring, where biotech...

1 min read

Meet Veristat at PHUSE US Connect: Advancing Data-Driven Clinical Development

Mar 18, 2026  Veristat Events

🔬 Connecting with the Global Clinical Data and Biostatistics Community

Veristat is pleased to attend PHUSE US Connect...